サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1397026

マクロライド系抗生物質市場：薬剤タイプ別、投与経路別、適応症別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Macrolide Antibiotics Market By Drug Type, By Route of Administration, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 306 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
マクロライド系抗生物質市場：薬剤タイプ別、投与経路別、適応症別、流通チャネル別：世界の機会分析と産業予測、2023-2032年
出版日: 2023年10月31日
発行: Allied Market Research
ページ情報: 英文 306 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

マクロライド系抗生物質市場は、2022年には56億米ドルと評価され、2023年から2032年までのCAGRは2.3％を示し、2032年には70億米ドルに達すると推定されます。

マクロライドは抗生物質の一種で、細菌感染の治療と管理に使用されます。これらの抗生物質化合物は、大環状ラクトン環にデオキシ糖が結合しています。エリスロマイシンは1952年に開発された最初のマクロライド系抗生物質で、ペニシリンアレルギーの患者やペニシリン耐性感染症の治療に使用されました。他のマクロライド系抗生物質には、ロキシスロマイシン、クラリスロマイシン、テリスロマイシン、アジスロマイシン、フィダキソマイシンなどがあります。FDAは様々な細菌感染症の治療にこれらの抗生物質の使用を承認しており、市場での需要を高めています。

マクロライド系抗生物質は、細菌のタンパク質合成を阻害することで作用します。これらの化合物は細菌の50Sリボソームサブユニットに結合し、細菌のタンパク質合成を停止させる。結合後、ペプチジルトランスフェラーゼという酵素がtRNAにアミノ酸を付加するのを阻害することで、mRNAの翻訳を阻害します。エリスロマイシンが最も使用されている抗生物質で、アジスロマイシン、クラリスロマイシンがこれに続く。その他の抗生物質は、連鎖球菌、ブドウ球菌、クロストリジウム、コリネバクテリア、リステリア、ヘモプラスなどの多くの細菌株に対して活性を示します。エリスロマイシンの活性スペクトルは狭く、グラム陽性菌と少数のグラム陰性菌に作用します。一方、クラリスロマイシンやアジスロマイシンは、ヘリコバクター・ピロリやタキソプラズマ・ゴンディなどのグラム陰性菌に有効です。

世界中で細菌感染症が増加していることが、マクロライド系抗生物質市場の成長を促す主な要因となっています。皮膚感染症、呼吸器感染症、性行為感染症などの細菌性疾患の有病率は顕著です。例えば、WHOによると、2020年の成人の新規淋菌感染者数は8,240万人と推定されています。淋病は一般的な性感染症であり、セックスワーカー、トランスジェンダー女性、青少年における罹患率が最も高いです。そのため、このような感染症の増加がマクロライド系抗生物質の需要を押し上げ、市場の成長に寄与しています。

しかし、細菌種間の抗菌剤耐性の増加が市場成長の妨げとなっています。マクロライド耐性菌の出現は、重症感染症の治療を困難にし、患者の死亡や入院期間の延長、治療に関する費用や経費の増加を招く可能性があります。マクロライド耐性菌による感染症が増加すると、治療薬が効かなくなるため、使用可能なマクロライド系薬剤の使用量が減少します。.これがマクロライド系抗生物質市場の成長を阻害する可能性があります。

しかし、マクロライド系薬剤に対する耐性菌の増加は、予測期間中の市場成長に有利な機会を提供すると予想されます。細菌が利用可能なマクロライド系抗生物質に対して耐性を持つようになったため、耐性を克服し、重度の細菌感染症の治療に有効な新規マクロライド系抗生物質の開発に対する需要が高まっています。このため、マクロライド系抗生物質に関する研究開発活動が活発化しており、今後数年間は市場成長の好機となることが期待されています。

利害関係者にとっての主なメリット

  • 当レポートは、2022年から2032年までのマクロライド系抗生物質市場分析の市場セグメント、現在の動向、推定・動向、力学の定量分析を提供し、マクロライド系抗生物質市場の有力な市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
  • マクロライド系抗生物質市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションの明確な理解を提供します。
  • 本レポートには、地域および世界のマクロライド系抗生物質市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

その他の特典は以下の通りです：

  • 四半期ごとの最新情報および*（法人向けライセンスでのみご利用いただけます。）購入前または購入後に、ご希望の企業プロファイルを5社追加で無料アップデート。
  • 5ユーザー・ライセンスおよびエンタープライズ・ユーザー・ライセンス購入の場合、次期バージョンを無料で提供。
  • アナリストによる16時間のサポート*（購入後、レポートのレビューで追加データ要件が見つかった場合、質問や販売後の問い合わせを解決するためにアナリストによる16時間のサポートを受けることができます）
  • 15％の無料カスタマイズ*（レポートの調査範囲またはセグメントがお客様の要件と一致しない場合、15％は3営業日の無料作業に相当します。）
  • 5ユーザーライセンスおよびエンタープライズユーザーライセンスの無料データパック。（エクセル版レポート）
  • レポートが6～12ヶ月以上前の場合、更新レポートを無料で提供。
  • 24時間優先対応*。
  • 業界の最新情報とホワイトペーパーを無料で提供

本レポートのカスタマイズが可能（別途費用とスケジュールがかかります。）

  • 規制ガイドライン
  • 顧客の関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • 主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 細菌感染症の増加
      • ジェネリック医薬品の入手可能性
      • 新興国からのマクロライドに対する大きな需要
    • 抑制要因
      • 抗菌薬耐性の増加
      • マクロライド系抗生物質に伴う副作用
    • 機会
      • 研究開発への投資の増加

第4章 マクロライド系抗生物質市場：薬剤タイプ別

  • 概要
  • アジスロマイシン
  • エリスロマイシン
  • その他

第5章 マクロライド系抗生物質市場：投与経路別

  • 概要
  • 経口剤
  • 非経口
  • その他

第6章 マクロライド系抗生物質市場：適応症別

  • 概要
  • 呼吸器感染症
  • 皮膚感染症
  • 性感染症
  • 消化器感染症
  • その他

第7章 マクロライド系抗生物質市場：流通チャネル別

  • 概要
  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンラインプロバイダー

第8章 マクロライド系抗生物質市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他

第9章 競争情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第10章 企業プロファイル

  • Abbott Laboratories
  • Pfizer Inc.
  • Alkem Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Wellona Pharma Private Limited.
  • Bristol Laboratories Ltd.
  • Crescent Pharma Limited
  • Merck & Co., Inc.
  • Zydus Lifesciences Limited
図表

LIST OF TABLES

  • TABLE 01. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 06. MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 10. MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. MACROLIDE ANTIBIOTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 25. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 28. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 32. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. UK MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. UK MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 53. UK MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 55. ITALY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. ITALY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 57. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 78. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 82. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 86. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 100. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 101. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 103. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 111. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 117. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 118. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 119. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 120. PFIZER INC.: KEY EXECUTIVES
  • TABLE 121. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 122. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 123. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 124. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 125. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 127. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 132. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 133. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 134. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 137. WELLONA PHARMA PRIVATE LIMITED.: KEY EXECUTIVES
  • TABLE 138. WELLONA PHARMA PRIVATE LIMITED.: COMPANY SNAPSHOT
  • TABLE 139. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT SEGMENTS
  • TABLE 140. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT PORTFOLIO
  • TABLE 141. BRISTOL LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 142. BRISTOL LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 143. BRISTOL LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 144. BRISTOL LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 145. CRESCENT PHARMA LIMITED: KEY EXECUTIVES
  • TABLE 146. CRESCENT PHARMA LIMITED: COMPANY SNAPSHOT
  • TABLE 147. CRESCENT PHARMA LIMITED: PRODUCT SEGMENTS
  • TABLE 148. CRESCENT PHARMA LIMITED: PRODUCT PORTFOLIO
  • TABLE 149. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 150. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 151. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 152. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 153. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 154. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 155. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 156. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 157. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 158. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. MACROLIDE ANTIBIOTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MACROLIDE ANTIBIOTICS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN MACROLIDE ANTIBIOTICS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN MACROLIDE ANTIBIOTICS MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL MACROLIDE ANTIBIOTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. MACROLIDE ANTIBIOTICS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 30. U.S. MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. MEXICO MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. GERMANY MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. FRANCE MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. UK MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. ITALY MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SPAIN MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. JAPAN MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. CHINA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. INDIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. BRAZIL MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: MACROLIDE ANTIBIOTICS MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2022
  • FIGURE 56. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 73. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A69591

The macrolide antibiotics market was valued at $5.6 billion in 2022 and is estimated to reach $7.0 billion by 2032, exhibiting a CAGR of 2.3% from 2023 to 2032. Macrolides are a class of antibiotics, used to treat and manage bacterial infections. These antibiotic compounds have a macrocyclic lactone ring attached with deoxy sugars. Erythromycin was the first macrolide antibiotic developed in 1952 and was used in the treatment of infections in patients allergic to penicillin and also in the case of penicillin resistant infections. Other macrolide antibiotics include roxithromycin, clarithromycin, telithromycin, azithromycin, fidaxomicin and others. The FDA has approved the use of these antibiotics in the treatment of various bacterial infections, which increases their demand in the market.

Macrolide antibiotics act by inhibiting bacterial protein synthesis. These compounds bind to the bacterial 50 S ribosomal subunit, causing the cessation of bacterial protein synthesis. After binding, the drug prevents the translation of mRNA, by inhibiting the enzyme peptidyl transferase from adding the subsequent amino acid attached to the tRNA. Erythromycin is the most used antibiotic, followed by azithromycin and clarithromycin. These antibiotics are active against many strains of bacteria such as streptococci, staphylococci, clostridia, corynebacteria, listeria, haemoplhillus, and others. Erythromycin has a narrow spectrum of activity with action against gram-positive and few gram-negative bacteria. On the other hand, clarithromycin and azithromycin are active against gram-negative bacteria such as helicobacter pylori, taxoplasma gondii and others.

Rise in incidences of bacterial infections around the globe is the major factor driving the growth of the macrolide antibiotics market. There is a significant prevalence of bacterial diseases such as skin infections, respiratory tract infections, sextually transmitted bacterial infection, and others. For instance, according to the WHO, there were an estimated 82.4 million new gonorrhoea infections among adults in 2020. Gonorrhoea is a common sexually transmitted infection having the highest incidence among sex workers, transgender women and adolescents. Thus, rise in incidences of such infections boost the demand for macrolide antibiotics, which contributes to the market growth.

However, rise in antimicrobial resistance among the bacterial species causes hindrance to the market growth. Emergence of macrolide resistant bacteria causes difficulty in treatment of severe infections, which may lead to the death of the patient, increase hospital stay, and increase the cost and expenses related to treatment. As the number of infections caused by macrolide resistant bacteria increases, drugs become ineffective for treatment and thus, there is a reduction in use of available macrolide medications. . This may hinder the growth of the macrolide antibiotics market.

However, a rise in antimicrobial resistance for macrolide class of drug is expected to offer lucrative opportunities for market growth during the forecast period. As bacteria are resistant to the available macrolide antibiotics, there is rise in demand for development of new novel macrolide antibiotics that may help overcome the resistance and thus, are effective in the treatment of severe bacterial infections. This increases R&D activities related to the macrolides and thus, is expected to offer lucrative opportunities for market growth in the coming years.

The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into azithromycin, erythromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of AsiaPacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited.

  • Key Benefits for Stakeholders
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the macrolide antibiotics market analysis from 2022 to 2032 to identify the prevailing macrolide antibiotics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the macrolide antibiotics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global macrolide antibiotics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

  • Azithromycin
  • Erythromycin
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Indication

  • Respiratory Tract Infections
  • Skin Infections
  • Sexually Transmitted Infections
  • Gastrointestinal Infections
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
    • Wellona Pharma Private Limited.
    • Sun Pharmaceutical Industries Limited
    • Bristol Laboratories Ltd.
    • Zydus Lifesciences Limited
    • Alkem Laboratories Ltd.
    • Crescent Pharma Limited
    • Merck & Co., Inc.
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidences of bacterial infections
      • 3.4.1.2. Availability of generic medications
      • 3.4.1.3. Significant demand for macrolides from emerging countries
    • 3.4.2. Restraints
      • 3.4.2.1. Rise in antimicrobial resistance
      • 3.4.2.2. Side effects associated with macrolide antibiotics
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in investments in research and development activities

CHAPTER 4: MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Azithromycin
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Erythromycin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Parenteral
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: MACROLIDE ANTIBIOTICS MARKET, BY INDICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Respiratory Tract Infections
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Skin Infections
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Sexually Transmitted Infections
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Gastrointestinal Infections
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Others
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country

CHAPTER 7: MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Drug Stores and Retail Pharmacies
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Online Providers
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: MACROLIDE ANTIBIOTICS MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Drug Type
    • 8.2.3. Market size and forecast, by Route of Administration
    • 8.2.4. Market size and forecast, by Indication
    • 8.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Drug Type
      • 8.2.6.1.2. Market size and forecast, by Route of Administration
      • 8.2.6.1.3. Market size and forecast, by Indication
      • 8.2.6.1.4. Market size and forecast, by Distribution Channel
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Drug Type
      • 8.2.6.2.2. Market size and forecast, by Route of Administration
      • 8.2.6.2.3. Market size and forecast, by Indication
      • 8.2.6.2.4. Market size and forecast, by Distribution Channel
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Drug Type
      • 8.2.6.3.2. Market size and forecast, by Route of Administration
      • 8.2.6.3.3. Market size and forecast, by Indication
      • 8.2.6.3.4. Market size and forecast, by Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Drug Type
    • 8.3.3. Market size and forecast, by Route of Administration
    • 8.3.4. Market size and forecast, by Indication
    • 8.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Drug Type
      • 8.3.6.1.2. Market size and forecast, by Route of Administration
      • 8.3.6.1.3. Market size and forecast, by Indication
      • 8.3.6.1.4. Market size and forecast, by Distribution Channel
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Drug Type
      • 8.3.6.2.2. Market size and forecast, by Route of Administration
      • 8.3.6.2.3. Market size and forecast, by Indication
      • 8.3.6.2.4. Market size and forecast, by Distribution Channel
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Drug Type
      • 8.3.6.3.2. Market size and forecast, by Route of Administration
      • 8.3.6.3.3. Market size and forecast, by Indication
      • 8.3.6.3.4. Market size and forecast, by Distribution Channel
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Drug Type
      • 8.3.6.4.2. Market size and forecast, by Route of Administration
      • 8.3.6.4.3. Market size and forecast, by Indication
      • 8.3.6.4.4. Market size and forecast, by Distribution Channel
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Drug Type
      • 8.3.6.5.2. Market size and forecast, by Route of Administration
      • 8.3.6.5.3. Market size and forecast, by Indication
      • 8.3.6.5.4. Market size and forecast, by Distribution Channel
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Drug Type
      • 8.3.6.6.2. Market size and forecast, by Route of Administration
      • 8.3.6.6.3. Market size and forecast, by Indication
      • 8.3.6.6.4. Market size and forecast, by Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Drug Type
    • 8.4.3. Market size and forecast, by Route of Administration
    • 8.4.4. Market size and forecast, by Indication
    • 8.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Drug Type
      • 8.4.6.1.2. Market size and forecast, by Route of Administration
      • 8.4.6.1.3. Market size and forecast, by Indication
      • 8.4.6.1.4. Market size and forecast, by Distribution Channel
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Drug Type
      • 8.4.6.2.2. Market size and forecast, by Route of Administration
      • 8.4.6.2.3. Market size and forecast, by Indication
      • 8.4.6.2.4. Market size and forecast, by Distribution Channel
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Drug Type
      • 8.4.6.3.2. Market size and forecast, by Route of Administration
      • 8.4.6.3.3. Market size and forecast, by Indication
      • 8.4.6.3.4. Market size and forecast, by Distribution Channel
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Drug Type
      • 8.4.6.4.2. Market size and forecast, by Route of Administration
      • 8.4.6.4.3. Market size and forecast, by Indication
      • 8.4.6.4.4. Market size and forecast, by Distribution Channel
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Drug Type
      • 8.4.6.5.2. Market size and forecast, by Route of Administration
      • 8.4.6.5.3. Market size and forecast, by Indication
      • 8.4.6.5.4. Market size and forecast, by Distribution Channel
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Drug Type
      • 8.4.6.6.2. Market size and forecast, by Route of Administration
      • 8.4.6.6.3. Market size and forecast, by Indication
      • 8.4.6.6.4. Market size and forecast, by Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Drug Type
    • 8.5.3. Market size and forecast, by Route of Administration
    • 8.5.4. Market size and forecast, by Indication
    • 8.5.5. Market size and forecast, by Distribution Channel
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Drug Type
      • 8.5.6.1.2. Market size and forecast, by Route of Administration
      • 8.5.6.1.3. Market size and forecast, by Indication
      • 8.5.6.1.4. Market size and forecast, by Distribution Channel
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Market size and forecast, by Drug Type
      • 8.5.6.2.2. Market size and forecast, by Route of Administration
      • 8.5.6.2.3. Market size and forecast, by Indication
      • 8.5.6.2.4. Market size and forecast, by Distribution Channel
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Market size and forecast, by Drug Type
      • 8.5.6.3.2. Market size and forecast, by Route of Administration
      • 8.5.6.3.3. Market size and forecast, by Indication
      • 8.5.6.3.4. Market size and forecast, by Distribution Channel
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Drug Type
      • 8.5.6.4.2. Market size and forecast, by Route of Administration
      • 8.5.6.4.3. Market size and forecast, by Indication
      • 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Abbott Laboratories
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Pfizer Inc.
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. Alkem Laboratories Ltd.
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Sun Pharmaceutical Industries Limited
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Teva Pharmaceutical Industries Limited
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
    • 10.5.7. Key strategic moves and developments
  • 10.6. Wellona Pharma Private Limited.
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
  • 10.7. Bristol Laboratories Ltd.
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. Crescent Pharma Limited
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
  • 10.9. Merck & Co., Inc.
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. Zydus Lifesciences Limited
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments